Bioleaders Corporation (142760) — Capital Reinvestment Ratio

Latest as of September 2024: 21.04x

Bioleaders Corporation (142760) has a Capital Reinvestment Ratio of 21.04x as of September 2024, meaning it reinvests 21% of its operating cash flow (₩49.56 Million) in capital expenditures (₩1.04 Billion). See 142760 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

21.04x
Capex / Operating Cash Flow

Operating Cash Flow

₩49.56 Million
KRW

Capital Expenditures

₩1.04 Billion
KRW

Data as of

Sep 2024
Most recent filing

Bioleaders Corporation Capital Reinvestment Ratio (2023–2023)

This chart tracks Bioleaders Corporation's Capital Reinvestment Ratio across 1 annual periods. Check Bioleaders Corporation (142760) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Bioleaders Corporation (2023–2023)

Year-by-year Capital Reinvestment Ratio for Bioleaders Corporation from 2023 to 2023. For live market cap and broader valuation context, see Bioleaders Corporation (142760) total market value.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2023 0.06x ₩6.18 Billion ₩378.81 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow